EMA Withdrawn: Onduarp (telmisartan) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The EMA withdrew Onduarp (telmisartan) from Boehringer Ingelheim International GmbH, with the decision in 2014, in the hypertension therapeutic area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Onduarp (telmisartan)

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Boehringer Ingelheim International GmbH. Decision date: 17/02/2014